Product
TAK-771
Aliases
Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
3 clinical trials
3 indications
Indication
Multifocal Motor NeuropathyIndication
Primary Immunodeficiency DiseasesClinical trial
A Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of TAK-771 for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN) in Japanese SubjectsStatus: Active (not recruiting), Estimated PCD: 2024-03-05
Clinical trial
A Phase 3, Open-label, Non-controlled, Extension Study to Evaluate the Long-term Safety of TAK-771 in Japanese Patients With Primary Immunodeficiency Disease (PID)Status: Active (not recruiting), Estimated PCD: 2025-04-30
Clinical trial
A Phase 3, Open-label, Non-controlled Study to Evaluate the Pharmacokinetics, Safety and Tolerability, and Efficacy of TAK-771 in Japanese Subjects With Primary Immunodeficiency Diseases (PID)Status: Completed, Estimated PCD: 2023-08-28